CTOs on the Move

Intouch Solutions

www.intouchsol.com

 
At Intouch Solutions, we know pharma marketing isn`t easy. But after more than a decade of hard work in this and similarly regulated industries, we think we understand that better than most. We have a pretty good idea of what it takes to connect your customers to your brand.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.intouchsol.com
  • 7045 College Blvd. Suite 300
    Overland Park, KS USA 66211
  • Phone: 913.317.9700

Executives

Name Title Contact Details

Similar Companies

DMD Pharmaceuticals

DMD Pharmaceuticals is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyra Medical

KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Curve™ Spine Frame The KYRA Curve has a class-...

Taylst

Taylst is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARTMS

ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world’s most-used diagnostic imaging isotopes.

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.